


African Journal of Biochemistry Research

Volume 11 Number 8, August 2017

ISSN 1996-0778



*Academic
Journals*

ABOUT AJBR

The African Journal of Biochemistry Research (AJBR) (ISSN1996-0778) is published Monthly (one volume per year) by Academic Journals.

African Journal of Biochemistry Research (AJBR) provides rapid publication (monthly) of articles in all areas of Biochemistry such as Nutritional biochemistry, Analytical biochemistry, Clinical Biochemistry, Human and Plant Genetics, Molecular and Cell Biology, Enzymology, Toxicology, Plant Biochemistry, Biochemistry Education etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles are peer-reviewed.

Contact Us

Editorial Office: ajbr@academicjournals.org

Help Desk: helpdesk@academicjournals.org

Website: <http://www.academicjournals.org/journal/AJBR>

Submit manuscript online <http://ms.academicjournals.me/>

Editor

Prof. Johnson Lin

*School of Biochemistry, Genetics, Microbiology
and Plant Pathology
University of KwaZulu-Natal (Westville)
Private Bag X 54001, Durban
Republic of South Africa*

Associate Editors

Gregory Lloyd Blatch

*Dept Biochemistry Microbiology & Biotechnology
Rhodes University Grahamstown 6140
South Africa*

Dr. Serap Yalin

*Mersin University,
Faculty of Pharmacy,
Department of Biochemistry,
Yenisehir Kampusu,
Mezitli 33161
Mersin/Turkey*

Dr. Om Prakash Gupta

*Directorate of Wheat Research (ICAR)
Post Box-158, A
grasain Marg, Karnal-132001, Haryana, India*

Editorial Board

Dr. Desouky A.M. Abd-El-Haleem
Biological Sciences Department,
College of Arts and Sciences,
Qatar University, Doha,
Qatar

Dr. S.K. Trigun
Biochemistry and Molecular Biology Section,
Banaras Hindu University
Varanasi-221005,
India

Dr. ImedGallouzi
McGill University,
Biochemistry Department,
3655 Promenade Sir William OslerMontreal,
Quebec, H3G 1Y6,
Canada

Dr. Ashraf A Khalil
Protein Technology Lab, Mubarak City for Science, New
Borg Elarab,
Alexandria,
Egypt.

Dr. Stanley Mukanganyama
Department of Biochemistry,
University of Zimbabwe, Box MP 167,
Mount Pleasant, Harare,
Zimbabwe

Prof. Salah A. Sheweita
Taibah University, Faculty of Medicine, Department of
Biochemistry, PO Box 30001, Madinah,
Saudi Arabia

Dr Oluwafemi O Oguntibeju
Department of Clinical Biochemistry,
School of Medicine,
Spartan Health Sciences University,
P.O. Box 324, Vieux Fort, St Lucia,
West Indies

Dr. Robert L. Brown
USDA ARS,
Southern Regional Research Center
1100 Robert E. Lee Blvd.,
New Orleans, LA 70124

Dr. Edward Eteshola
Biomedical Engineering Center
Davis Heart and Lung Research Institute
Ohio State University
473 W. 12th Avenue
Columbus, OH 43210

G. Suresh Kumar
Senior Scientist and Head
Biophysical Chemistry Laboratory
Indian Institute of Chemical Biology
Council of Scientific and Industrial Research
Jadavpur,
Kolkata 700 032,
India

Xu Lu
Department of Biochemistry and Molecular Biology
Colorado State University
Fort Collins,
CO 80523-1870
USA

Mohammed A.A Sarhan
Dept. Biological Sciences
Faculty of Science
King Khalid University
Saudi Arabia

MehrdadBehmanesh
Department Of Genetics
School Of Science
P.O.Box 114-175 Tehran Iran
Iran

Hans Verhagen
P.o Box 1 3720 Ba Bilthoven
The Netherlands
Netherlands

P.K.Sumodan
Post Graduate Department Of Zoology
Government College Madappally India
India

BalesengMoseki
University Of Botswana
Botswana

Bhaskar C. Behera

*Agharkar Research Institute
Plant Science Division India
India*

Luiz Claudio Miletti

*Universidade Do Estado De Santa Catarina
Brasil*

Oladipo Gabriel Sunday

*University Of Port Harcourt
Port Harcourt-Nigeria
Nigeria*

Basiouny Ahmed El-Gamal

*Biochemistry Department
Faculty Of Science
Alexandria University
Egypt*

AminigoEbiokpo Rebecca

*University Of Port Harcourt
Portharcourt-Nigeria
Nigeria*

JiaZeng

*Department Of Bioengineering
Central South University
Changsha Hunan 410083 P.R.China
China*

Adenike Kuku

*ObafemiAwolowo University
Department Of Biochemistry
Nigeria*

Elsayed Hafez

*Genetic Engineering and Biotechnology Research Institute
Egypt*

Gabriella Castoria

*Via L. De Crecchio 7 -80138 Naples
Department Of General Pathology
Italy*

SalwaSeddik Abdel-Latif

*21 Elbatal Ahmed Abdel Aziz
Elmohandesien Giza
Egypt*

Erasto Vitus Mbugi

*Muhimbili University
Biochemistry Department
School Of Medicine
India*

Mohamed Rholam

*Université Paris7 - Denis-Diderot
France*

Hooi Ling Foo

*Universiti Putra Malaysia
Malaysia*

JayanthRao

*Biochemistry And Nutrition
Cftri Mysore
India*

Maznah Ismail

*Universiti Putra
Malaysia*

Svetlana Lutsenko

*Oregon Health & Science University
USA*

Gabriel Ugwem

*Rivers State University Of Science And Technology
P.M.B. 5080 Port Harcourt
Nigeria*

HariChhatpar

*Dept. Of Microbiology & Biotechnology Centre
Faculty Of Science
M.S.University Of Baroda
Vadodara 390 002
Baroda India*

MahiuddinAlamgir

*The University Of New South Wales
Sydney Nsw-2052
Australia*

Sheeja Samuel Edwin

*B.R Nahata College of Pharmacy & Research Centre
India*

William Cho

*Room 1305 13/F Block R Department of Clinical Oncology
Queen Elizabeth Hospital
30 Gascoigne Road Kowloon
Hong Kong*

Dr. SurainiAbd-Aziz
*Universiti Putra Malaysia
Malaysia*

Dr. Mustafa NumanBucak
*Lalahan Livestock Central Research Institute Lalahan
Ankara Turkey*

Alparslan Kadir Devrim
*Department Of Biochemistry
Faculty of Veterinary Medicine
Kafkas University 36040 Kars
Turkey*

Vasudev R. Thakkar
*Sardar Patel University
Brd School of Biosciences
Sardar Patel University
Nagar*

Prof. Emmanuel Anosike
*Department Of Biochemistry
University Of Port Harcourt
Nigeria*

Dr. Usama Beshay
*New Bourg El-Arab City, Research Area
Alexandria 21934
Egypt*

Dr. Ramar Perumal Samy
*Department of Anatomy
Yong Loo Lin School of Medicine
National University of Singapore
Singapore*

Dr. Shin-ichi ONO
*Laboratory of Clinical Pharmacy
College of Pharmacy, Nihon University
Japan*

Prof. Lawal Bilbis
*Biochemistry Department
UsmanuDanfodiyo University Sokoto
Nigeria*

Dr. Adriana G. Chicco
*Department of Biochemistry
University of Litoral, Santa Fe
Argentina*

Prof. Zia-Ur Rahman
*Department Of Physiology and Pharmacology
University Of Agriculture
Faisalabad
Pakistan*

Dr. Oluwole Ariyo
*Allen University
USA*

Prof. Francisco Torrens
*Institut Universitari de Ciència Molecular
Universitat de València
Spain*

Prof. Belkhodja Moulay
*University of Senia Oran
Algeria*

Dr. Hossam M Ashour
*Department of Microbiology and Immunology
Faculty of Pharmacy, Cairo University
Egypt*

Dr. Fidelis Ocloo
*Biotechnology and Nuclear Agriculture Research
Institute/GAEC
Ghana*

Ass. Prof. Alfonso Baldi
*Dept. Biochemistry, Sect. Pathology
Second University of Naples,
Italy*

Dr. Anandh Babu Pon Velayutham
*Department of Human Nutrition
Foods and Exercise 253 Wallace Hall Virginia Tech
Blacksburg VA 24061
USA*

Dr. Tapan K. Chaudhuri
*Department of Biochemical Engineering and Biotechnology
Indian Institute of Technology Delhi, HauzKhas
New Delhi-110016, India.*

Dr. Rong Zhang
*Shenyang Pharmaceutical University
China*

Ass. Prof. Tzong-Jih Cheng
Department of Bio-Industrial Mechatronics
National Taiwan University
Taiwan

Dr. Zuyong Xia
Department of Radiology,
1201 Welch Rd, Room P089, Stanford, CA 94301
USA

Dr. Pratap Kumar Das
Indian Institute of Chemical Biology
India

Dr. Vasudeo Pandharinath Zambare
Advanced Enzyme Technologies Ltd
India

Dr. A M Mujumdar
Agharkar Research Institute
India

Prof. Christine Clayton
ZMBH
ImNeuenheimer Feld 282
69120 Heidelberg
Germany

Prof. Rekik Boul baba
ESA Mateur
Département des sciences et techniques de productions
animales
Tanzania

Dr. Farhad Mirzaei
National Dairy Research Institute, NDRI
Karnal
India

Dr. ROUABHI Rachid
Biology Department
Tebessa University.
Algeria

Prof. Vaclav Vetvicka
University of Louisville
USA

Dr. Ramesh Putheti, Ph.D
Research scientist
Actavis Pharmaceuticals
10065 red run blvd,owings mills Blvd,Maryland.U.S.A.21030
USA

Prof. Dr. Mustafa NAZIROGLU
Head of Department of Biophysics
Medical (TIP) Faculty, SuleymanDemirel University
Cunur, TR-32260 Isparta
TURKEY

Dr. José Luis Arias Mediano
GrupoInvestigaciónFarmaciaPráctica (CTS-205)
Dept. Farmacia y TecnologíaFarmacéutica
Facultad de Farmacia
Campus Universitario de Cartuja, s/n Universidad de
Granada
18071 Granada.

Ahmed Malki, PhD
Lecturer of Biochemistry and Molecular Biology
Biochemistry Department
Faculty Of Science
Alexandria University
Alexandria,
Egypt

Dr. Alireza Seidavi (PhD)
Assistant Professor of Animal and Poultry Nutrition,
Department of Animal Science,
College of Agriculture,
Islamic Azad University, Rasht Branch,
Rasht, Iran

Amani S. Awaad
Professor of pharmacognosy, Chemistry Department
Faculty of Sciences, King Saud University .
Riyadh. KSA. P.O. Box 22452, Riyadh 11495.
Saudi Arabia

Dr. Abdel-TawabMossa
Environmental Toxicology Research Unit (ETRU),
Pesticide Chemistry Department,
National Research Centre,
Dokki,
Egypt

Dr. Amal A. Mohamed

*Plant Biochemistry Department,
Agriculture Division - National Research Center,
31-El-Tahrir St.,
Dokki,
Cairo – Egypt*

Dr. Anabella Gaspar

*Department of Biochemistry,
University of Pretoria,
South Africa*

Dr. Anna Janecka

*Department of Biomolecular Chemistry,
Medical University of Lodz,
Mazowiecka 6/8,
92-215 Lodz,
Poland*

Dr. Caser Abdel

*Horticulture Department,
Dohuk University,
Iraq*

Dr. David Sheehan

*Dept Biochemistry,
University College Cork,
Ireland*

Dr. Dayananda Chandrappa

*Center for Bioenergy,
Department of Life and Physical
Sciences,
Cooperative Research,
Lincoln University,
Jefferson City,
USA*

Dr. Elsayed Abdelaal

*Special Graduate Faculty,
University of Guelph,
Onatio,
Canada*

Dr. Etienne Marbaix

*CELL Unit,
de Duve Institute,
UCL-75.41, 75 avenue
Hippocrate,
B-1200 Bruxelles,
Belgium*

Dr. Gary L. Firestone

*Department of Molecular and Cell Biology,
University of California,
Berkeley,
CA, 94720,
USA*

Dr. Henryk Zielinski

*Institute of Animal Reproduction and Food Research,
Polish Academy of Sciences,
Poland*

Dr. Irshad A. Nawchoo

*Department of Botany,
University of Kashmir,
India*

Dr. LuchaiButkhup

*Department of Biotechnology,
Faculty of Technology,
Mahasarakham University,
Mahasarakham 44000,
Thailand*

Dr. LuminitaVladescu

*Department of Analytical Chemistry,
Faculty of Chemistry,
University of Bucharest,
Romania*

Dr. Mira Debnath

*School of Biochemical Engineering,
Institute of Technology - Banaras Hindu University,
Varanasi,
India*

Dr. Nilesh S. Panchal

*Department of Biosciences,
Saurashtra University,
Rajkot-360005,
Gujarat.
India*

Dr. Rayappa A. Balikai

*University of Agricultural Sciences,
Dharwad,
Karnataka- 580 005,
India*

Dr. SaadTayyab

*Institute of Biological Sciences,
University of Malaya,
50603 Kuala Lumpur,
Malaysia*

Dr. Shijun Fu

*Institute of Health Sciences,
Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences and Shanghai Jiao Tong
University School of Medicine, Shanghai,
P. R. China*

Dr. Shiming Zhang

*Weis Center for Research,
Geisinger Clinic,
Danville, Pennsylvania,
USA*

Dr. Thomas Efferth

*Department of Pharmaceutical Biology,
Institute of Pharmacy and Biochemistry,
University of Mainz, Heidelberg,
55128 Mainz,
Germany*

ARTICLE

- Haptoglobin polymorphism and cardiovascular risk factors in followed epileptic patients at Fann National University Hospital** 43
Papa Madièye GUEYE, Moustapha DJITE, El Hadji Malick NDOUR, Fatou GUEYE-TALL, Néné Oumou Kesso BARRY, Aïssatou SARR, Rokhaya NDIAYE DIALLO, Philomène LOPEZ SALL, Aynina CISSE and Pape Amadou DIOP

Full Length Research Paper

Haptoglobin polymorphism and cardiovascular risk factors in followed epileptic patients at Fann National University Hospital

Papa Madièye GUEYE^{1,2*}, Moustapha DJITE², El Hadji Malick NDOUR¹, Fatou GUEYE-TALL¹, Néné Oumou Kesso BARRY², Aïssatou SARR², Rokhaya NDIAYE DIALLO¹, Philomène LOPEZ SALL¹, Aynina CISSE¹ and Pape Amadou DIOP¹

¹Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.

²Laboratory of Biochemistry, University Hospital Fann, Dakar, Senegal.

Received 19 March, 2017; Accepted 12 July, 2017

The aim of our research was to evaluate the cardiovascular risk factors on epileptic patients treated at the Fann University Hospital and to study the influence of haptoglobin (Hp) polymorphism on disease progression. In order to do that, eighty-six (86) patients followed in neurology for at least 2 years were recruited. Each patient was matched to a control according to age and sex. Hp phenotyping was performed by electrophoresis on polyacrylamide gel, and lipid peroxidation was quantified by the dosage of the thiobarbituric acid reacting substances (TBARS). The determination of a number of biochemical parameters was performed in both patients and controls. The evaluation of lipid parameters showed significant differences in total cholesterol levels, triglycerides, low-density lipoprotein (LDL) cholesterol and atherogenic index between patients and controls. For C-Reactive Protein-ultra sensible (CRP-us) values greater than 3 mg / L, a statistically significant difference was found ($p = 0.009$). The frequencies of the three major phenotypes of patients compared to controls has shown significant difference only for Hp2-2 phenotype ($p = 0.042$). The significant increase of TBARS for patients compared to controls suggested an oxidative mechanism. Results have shown a risk of developing cardiovascular diseases during the progression of epilepsy. The influence of Hp polymorphism in modulating oxidative stress suggests that taking antioxidants may have a beneficial effect, especially in patients of phenotype Hp2-2.

Key words: Epilepsy, haptoglobin polymorphism, cardiovascular risks.

INTRODUCTION

Epilepsy is considered as one of the most widespread diseases in the world with a prevalence of 0.5 to 1% in

the population (Hauser et al., 1991). It is a chronic pathology that often requires long-term antiepileptic drug

*Corresponding author: E-mail: papamadieye.gueye@ucad.edu.sn. Tel: +221 77 8 19 74 07.

therapy (McCorry et al., 2004). This long-term therapy poses a dilemma for practitioner since it was reported that it is associated to an endothelial dysfunction with the appearance of adverse reactions that can accelerate the occurrence of atherosclerosis (Hamed et al., 2007; Tan et al., 2009).

Oxidative stress was recognized as an important factor in the onset of atherosclerosis (Stocker and Keane, 2004). Indeed, the role of low-density lipoprotein (LDL) oxidation in the transformation of macrophages into foam cells was one of the key points of the genesis of the atheromatous plaque (Moatti, 2003). This oxidative stress was potentially involved in many diseases as a trigger, or associated to complications in their evolution. If it is the case, it is logical to think that taking antioxidants or the intervention of an antioxidant mechanism may delay or prevent the appearance of such diseases.

The severity of oxidative stress and the ability of the body to reduce it may explain differences in susceptibility at the occurrence of atherosclerosis (Melamed-Frank et al., 2001). Therefore, the functional polymorphism of genes encoding certain enzymes and / or proteins may play a particularly important role in explaining the differences in susceptibility among patients with different phenotypes of epilepsy. Haptoglobin is a plasma protein encoded by two alleles rated 1 and 2; it has an antioxidant power which is a dependent phenotype (Melamed-Frank et al., 2001; Mackellar and Vigerust, 2016). The study of the Hp polymorphism effects on the progression of various diseases has been the subject of numerous researches in cardiovascular diseases, diabetes, infectious diseases, hematological and neurological disorders (Gogishvili et al., 1985; Guetta et al., 2007).

Apart from all the conditions mentioned above, the influence of Hp polymorphism on the development of many diseases, including neurological ones epilepsy (Panter et al., 1984), and lung or ovary cancers (Langlois and Delanghe, 1996; Anderson et al., 2009) was studied. Hp 2-2 phenotype cases have an increased susceptibility to adverse developments, compared with other phenotypes in these pathologies. Clinically, the 2-2 phenotype is associated with the risk of cardiovascular diseases and diabetes mellitus in patients (Tseng et al., 2004). The diabetic patients with the Hp 1-1 phenotype are markedly resistant to the development of diabetic retinopathy, diabetic nephropathy, and cardiovascular disease (Levy et al., 2000; Nakhoul et al., 2001). In a prospective study, participants homozygous for the Hp 2-2 allele had a 5-fold increased risk for the development of cardiovascular diseases as compared to participants homozygous for the Hp 1-1, allele (Asleh et al., 2003). The risk in heterozygous Hp 2-1 participates is intermediate (Asleh et al., 2003).

The aim of this research was to study the frequency of major Hp phenotypes in epileptic patients treated at the University Hospital of Fann and evaluate the number of

cardiovascular risk factors.

METHODS

This is an analytical prospective study. Eighty-six (86) patients followed at the Neurological Clinic of the Hospital University-Fann for at least two years and with good adherence were recruited. Each patient was matched to a control according to age and sex. Controls were recruited at the National Blood Transfusion Center. During the recruitment, patients were informed about the objectives of the study and were recruited after consent. This work received the approval of the local ethical committee.

The blood sample was taken by venipuncture on subjects at rest, at the elbow crease after fasting for at least 12 h. The blood was collected into a tube containing an anticoagulant mixture (ethylenediaminetetraacetate, EDTA) and antiglycolytic (sodium fluoride, NaF), and another tube without anticoagulant or antiglycolytic. All tubes were centrifuged at 3000 revs/min for 5 min. Serum and plasma were then packaged in NUNCK® tubes and stored at -20° C until dosage.

In patients and controls, cardiovascular risk factors, conventional lipid parameters and C-Reactive Protein-ultra sensible (CRP-us) were determined as. Besides these parameters, other parameters such as blood glucose, creatinine, urea and CRP were determined.

Hp phenotyping was performed by polyacrylamide gel electrophoresis followed by peroxidase staining according to Raymond method (Raymond, 1962). Samples were prepared by mixing 75 µL of plasma with 75 µL of a freshly prepared human Hb solution (1.6 µmol/L) and 100 µL of 0.29 mol/L sucrose. The samples were incubated for 10 min at room temperature and 10 µL of 0.001% (w/v) bromophenol blue were added to each sample prior the running on the gel. The electrophoresis of Hp-Hb complex was performed on a 5% polyacrylamide gel with running buffer containing 0.1 mol/L Tris and 0.09 mol/L boric acid, pH 8.4. Electrophoresis was run at a constant voltage of 200 V for 2 h. Afterwards, the Hp-Hb complexes were stained using their peroxidase activity by soaking the gel in a staining solution prepared by adding 0.2 g of dimethoxybenzidine to 100 mL of acetic acid solution (0.9 mol/L). After 2 h incubation in the dark at 37°C, 5 mL of 3% hydrogen peroxide (w/v), freshly prepared, were mixed with the solution covering the gel (100 mL); the bands corresponding to the Hp-Hb complexes, characteristic for each phenotype, were readily visible within 15 min.

The determination of total cholesterol, HDL-C, LDL cholesterol and triglycerides were made from a type of controller on Cobas C111 (Roche, Basel, Switzerland) with the manufacturer's reagents. The assay for TBARS was performed according to Yagi's method (Yagi, 1976), but modified (Conti, 1991). Briefly, 50 µl of each sample were mixed with 100 µl of TBA and trichloroacetic acid (TCA) in HCl to precipitate protein. The reaction was performed at pH 2 to 3 at 95°C for 20 min.

TBARS were extracted by the addition of 500 µl of n-butanol, then centrifuged at 1000 g for 5 min. Fluorescence of the butanolic phase was measured at 553 with a 532-nm excitation wavelength using an SFM 25 spectrofluorimeter (Kontron Inst., Montigny Le Bretonneux, France). Results were expressed in nmol of TBARS. A standard curve was produced using 1,19,3,39- tetraethoxypropane.

Statistical analysis

Statistical analyzes were performed thanks to Statview software using the Mann Whitney test to compare variables between patients and controls. The Kruskal Wallis test helped to determine significant differences among varying types of haptoglobin phenotypes. A p-value less than 0.05 was considered significant.




Figure 1. Comparison of average lipid parameters between epileptic patients and controls.




Figure 2. Comparison of average of CRP-us between epileptic patients and controls.

RESULTS

The study included 86 patients with 86 matched controls with a predominance of women (53%). The average age of the patients was 30.1y/o. A prevalence of generalized seizures (63%) versus partial seizures (37%) was found.

Evaluation of lipid parameters showed statistically significant differences between patients and controls (Figure 1) with regard to triglycerides ($p = 0.0066$), total cholesterol ($p = 0.012$) and LDL-cholesterol ($p = 0.001$), with the exception of HDL cholesterol ($p = 0.1560$).

Analysis of CRP and CRP-us results did not show statistically significant differences between patients and controls. However, the CRP-us values above 3 mg (Figure 2) was considered corresponding to a high-risk factor for cardiovascular diseases, a statistically significant difference was found ($p = 0.0077$).

The study of the Hp polymorphism revealed frequencies of 41.48% for Hp2-2 phenotypes, 32.36% for Hp1-1 and 23.16 for Hp2-1. Concerning controls, frequencies of 39.62, 45.07 and 13.31% were respectively found for Hp1-1 phenotype, Hp2-1 and Hp2-2. The frequencies




Figure 3. Comparison of TBARS level between epileptic patients and controls.

of the three major phenotypes of patients compared to controls showed significant difference only for Hp2-2 phenotype ($p = 0.042$); the other two phenotypes differences did not appear significant.

Analysis of the results of urea and creatinine showed a statistically significant difference between patients and controls ($p < 0.0001$). However, no pathological value was noticed in both groups. On the other side, the Hp2-2 phenotype of patients had a significant increase in serum creatinine compared to Hp1-1 and Hp2-1 phenotypes. This difference was not found in controls.

The comparison of results between patients and controls showed no statistically significant differences ($p = 0.267$). The evaluation of oxidative stress through the TBARS dosage showed a statistically significant difference between patients and controls $p < 0.001$ (Figure 3).

When the distribution was made according to the Hp phenotype, the Hp2-2 phenotype subjects showed elevated TBARS rates compared to other types of Hp but the differences were not found to be significant.

DISCUSSION

The aim of this study was to evaluate the cardiovascular risk factors, oxidative stress and the influence of haptoglobin polymorphism in epileptic patients at the National University Hospital-Fann.

In order to do that, 86 patients with 86 matched controls were recruited. In this study cohort, a predominance of men (53%) compared to women (47%) was observed. This predominance of men has been

reported by some authors (Ngoungou et al., 2006). This finding could be explained by an under-reporting of the disease among young women of marrying age. It has been reported by Ngoungou et al. (2006) that among six studies, four have taken place in Nigeria with a predominance of female. The hypothesis of a rural exodus from men (Osuntokun et al., 1982, Osuntokun et al., 1987) or a higher male mortality (Rwiza et al., 1992) may explain this finding.

In the study cohort, the average age is 30.1 years. This value is similar to the one found by N'diaye (2010) which is 30 years. However, several authors have reported an early age of epilepsy, which occurs before the age of 20 in more than 60% of the cases. The bimodal distribution found in industrialized countries does not appear to exist in sub-Saharan Africa (Ngoungou et al., 2006). In few studies, the proportion of elderly patients is still low; this could be explained by a lower life expectancy, which limits the study of incidence rates in the higher age groups (Tekle-Haimanot et al., 1997).

A prevalence of generalized seizures (63%) was found compared to partial seizures (37%). These results are similar to those reported by Fall et al. (2015) who noted frequencies of around 67 and 33%, respectively for generalized seizures and partial seizures (Fall et al., 2015; Isnard et al., 2000; Aaberg et al., 2016).

In sub-Saharan Africa, many studies have reported a predominance of generalized seizure. Sub-medicalization and more specifically the absence of neurologist and Electroencephalography apparatus could be the cause of a poor classification of crises (Ngoungou et al., 2006).

This study was interested in cardiovascular risk factors such as the type of lipid abnormalities and the dosage of

the CRP-us.

The evaluation of lipid parameters showed statistically significant differences between patients and controls with regard to triglycerides ($p = 0.0066$), total cholesterol ($p = 0.012$) and LDL-cholesterol ($p = 0.001$), with the exception of HDL cholesterol ($p = 0.1560$).

These results would suggest an exposure of patients with cardiovascular disease during the treatment. This was reported by Tan et al. (Tan et al., 2009) who reported an exposure to the occurrence of cardiovascular diseases via changes in lipid parameters.

Indeed, dyslipidemia has been known as one of the major risk factors in the development of atherosclerosis (Kullo and Ballantyne, 2005), and LDL cholesterol plays an important role in the atherosclerotic process by increasing the endothelial permeability, lipoprotein retention in the intima of blood vessels, and the recruitment of foam cells (Kullo and Ballantyne, 2005; Stocker and Keane, 2004).

In addition to these results, some authors have reported a negative influence of long-term treatment on lipid profile of epileptic patients (Isojärvi et al., 1993; Eiris et al., 1995; Nikolaos et al., 2004).

Analysis of CRP and CRP-us results did not show statistically significant differences between patients and controls.

However, when CRP-us values above 3 mg (corresponding to a high-risk factor for cardiovascular disease) was considered, a statistically significant difference was found ($p = 0.0077$). This is similar to the results found by Tan et al. (2009).

The association of the results on the evaluation of lipid parameters and CRP-us, an independent risk factor predictive of the rate of increase of atherosclerosis, would suggest that a long-term therapy with antiepileptic exposes to the occurrence of cardiovascular disease in epileptic patients.

Indeed, it has been reported that antiepileptic medication such as phenobarbital, carbamazepine and valproate contribute to an acceleration of atherosclerosis by changing the metabolism of homocysteine and folic acid (Schwaninger et al., 1999; Attilakos et al., 2006; Hamed et al., 2007; Stocker and Keane, 2004). Furthermore, high plasma homocysteine is an independent risk factor for the progression of atherosclerosis (Hassan et al., 2004; Temple et al., 2000).

The study of the seizure's frequency in the study population shows a predominance of Hp2-2 (60.52%) compared to Hp2-1 (26.31%) and Hp1-1 (18.41%). These results are similar to those found by other authors (Sadzadeh et al., 2004; Ilzecka, 1996; Al-Balaghee et al., 2015). Indeed, they found a significant relation between the Hp2-2 phenotype and the frequency of seizures. In their studies, 67% of epileptic patients with one or more seizures had the Hp2-2 phenotype. Saccucci et al. (2004) found an under-representation of phenotypes Hp2-1 and Hp1-1 in two populations of children with

generalized epilepsy, compared to controls.

These results, compared to those found in this study, suggest that the Hp2-2 phenotype cases would be more subject to seizures than those with other phenotypes. The evaluation of oxidative stress through the TBARS dosage showed a statistically significant difference between patients and controls ($p < 0.001$). Indeed, the auto-oxidation of the homocysteine promotes an overproduction of reactive oxygen species and hinders the cellular mechanisms of antioxidant defenses (Tyagi et al., 2006). This indicates that the oxidative mechanisms play an important role in the pathogenesis of cardiovascular diseases.

The diversity in antioxidant activity of the Hp phenotypes may explain, in part, the clinical outcome by which Hp phenotype is associated with differential susceptibility to free-radical related atherosclerosis and autoimmune disorders [Levy et al., 2002; Bernard et al., 1997]. A correlation between phenotype-dependent modulation of oxidative stress and prostaglandin synthesis has been reported (Bernard et al., 1997).

Urea and creatinine results showed a significant difference between patients and controls ($p < 0.0001$). However, no pathological value was noticed in both groups. In the other side, patients with Hp2-2 phenotype have shown a significant increase in serum creatinine compared to those with Hp1-1 and Hp2-1 phenotypes. This difference have not found in controls.

The comparison of results between patients and controls showed no statistically significant differences ($p = 0.267$).

Conclusion

The overall results suggest that there is a risk of occurrence of cardiovascular diseases in the evolution of epilepsy, and therefore the monitoring of renal function and lipid parameters is appropriate in this pathology. In addition, the results highlight the influence of Hp polymorphism in modulating oxidative stress and suggest that taking antioxidants could have a particularly beneficial effect on patients with Hp2-2 phenotype.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

REFERENCES

- Aaberg KM, Bakken IJ, Lossius MI, Lund-Søraas C, Håberg SE, Stoltenberg C, Suren P, Chin R (2016). Comorbidity and Childhood Epilepsy: A Nationwide Registry Study. *Pediatrics* 138(3): pii:e20160921.
- Al-Balaghee S, Al-Balaghee Z, Shabani A, Ghadam P, Bandehpour M, Askari Mehr A, Kazemi B (2015). Determination of haptoglobin genotype in an Iranian population with idiopathic generalized

- epilepsy. *Rep. Biochem. Mol. Biol.* 3(2):51-55.
- Anderson GD, Temkin NR, Dikmen SS, Diaz-Arrastia R, Machamer JE, Fahrhnenbruch C, Miller JW, Sadrzadeh SMH (2009). Haptoglobin Phenotype and Apolipoprotein E Polymorphism: Relationship to Post-Traumatic Seizures and Neuropsychological Functioning after Traumatic Brain Injury. *Epilepsy Behav.* 16(3):501-506.
- Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkovicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. (2003). Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. *Circ. Res.* 92(11):1193-200.
- Attilakos A, Papakonstantinou E, Schulpis K, Voudris K, Katsarou E, Mastroyianni S, Garoufi A (2006). Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. *Epilepsy Res.* 71:229-232.
- Bernard DR, Langlois MR, Delanghe JR, De Buyzere ML (1997). Evolution of haptoglobin concentration in serum during the early phase of acute myocardial infarction. *Euro. J. Clin. Chem. Clin. Biochem.* 35(2):85-88.
- Conti M, Morand PC, Levillain P, Lemonnier A (1991). Improved Fluorometric. *Clin. Chem.* 37(7):1273-1275.
- Eiris JM, Lojo S, Del Rio MC, Novo I, Bravo M, Pavon P, Castro-Gago M (1995). Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. *Neurology* 45:1155-1157.
- Fall M, Toure K, Seck LB, Ndiaye M, Diop AG, Ndiaye MM (2015). Profil épidémiologique et prise en charge socioéconomique des patients vivant avec l'épilepsie à Dakar, Sénégal. *La Tunisie Médicale.* 93(2):101-103.
- Gogishvili AV, Kavtaradze, VG, Mamaladze GT, Arutiunova MS, Takadze GSH (1985). Haptoglobin phenotype distribution in patients at high risk of developing myocardial infarct. *Kardiologia* 25(2):55-58.
- Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP (2007). Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free haemoglobin. *Atherosclerosis* 191(1):48-53.
- Hamed SA, Hamed EA, Hamdy R, Nabeshima T (2007). Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. *Epilepsy Res.* 74:183-192.
- Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS (2004). Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. *Brain* 127:212-219.
- Hauser WA, Annegers JF, Kurland LT (1991). Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. *Epilepsia* 32:429-445.
- Ilzecka J (1996). The biological role of haptoglobin and behaviour of this protein in different diseases, with special attention paid to brain stroke. *Ann. Univ. Mariae Curie Sklodowska Med.* 51:115-121.
- Isnard J, Guenot M, Ostrowsky K, Sindou M, Manguiere F (2000). The role of the insular cortex in temporal lobe epilepsy. *Ann. Neurol.* 48(4):614-623.
- Isojärvi JI, Pakarinen AJ, Myllylä VV (1993). Serum lipid levels during carbamazepine medication. A prospective study. *Arch. Neurol.* 50:590-593.
- Kullo IJ, Ballantyne CM (2005). Conditional risk factors for atherosclerosis. *Mayo Clin. Proc.* 80:219-230.
- Langlois MR., Delanghe JR (1996). Biological and clinical significance of haptoglobin polymorphism in humans. *Clin. Chem.* 42(10):1589-1600.
- Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV (2002). Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. *J. Am. Coll. Cardiol.* 40(11):1984-1990.
- Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, Skorecki K (2000). Haptoglobin phenotype and vascular complications in patients with diabetes. *N. Engl. J. Med.* 343:969-670.
- MacKellar M, Vigerust DJ (2016). Role of Haptoglobin in Health and Disease: A Focus on Diabetes. *Clin. Diabetes* 34:148-157.
- McCorry D, Chadwick D, Marson A (2004). Current drug treatment of epilepsy in adults. *Lancet Neurol.* 3:729-735.
- Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM (2001). Structure-function analysis of the antioxidant properties of haptoglobin. *Blood* 98(13):3693-3698.
- Moatti N. (2003). Athérosclérose : concepts actuels. In: Delattre J, Durand G, Jardillier JC. *Biochimie pathologique: 83-90.* Flammarion Médecine-Sciences, Paris, 2003.
- N'diaye S (2010). Les hallucinations dans les épilepsies partielles à propos de 31 cas Mémoire du CES de Neurologie. Université Cheikh Anta Diop, Dakar, n°331.
- Nakhoul FM, Zoabi R, Kanter Y, Zoabi M, Skorecki K, Hochberg I, Leibur M, Miller B, Levy AP (2001). Haptoglobin phenotype and diabetic nephropathy. *Diabetologia* 44(5):602-604.
- Ngoungou EB, Quet F, Dubreuil CM, Marin B, Houinato D, Nubukpo P, Dalmay F, Millogo A, Nsengiyumva G, Kouana-Ndouongo P, Diagona M, Ratsimbazafy V, Druet-Cabanac M, Preux PM (2006). Épidémiologie de l'épilepsie en Afrique subsaharienne : une revue de la littérature. *Epilepsies* 18(1):25-40.
- Nikolaos T, Stylianos G, Chryssoula N, Irini P, Christos M, Dimitrios T, Konstantinos P, Antonis T (2004). The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. *Med. Sci. Monit.* 10:MT50-MT52.
- Osuntokun BO, Adeuja AO, Nottidge VA (1987). Prevalence of the epilepsies in Nigerian Africans: a community-based study. *Epilepsia* 28:272-279.
- Osuntokun BO, Schoenberg BS, Nottidge VA, Adeuja A, Kale O, Adeyefa A, Bademosi O, Olumide A, Oyediran ABO, Pearson CA, Bolis CL (1982). Research protocol for measuring the prevalence of neurologic disorders in developing countries, results of pilot study in Nigeria. *Neuroepidemiology* 1(3):143-153.
- Panter SS, Sadrzadeh SM, Hallaway PE, Haines J, Anderson VE, Eaton JW (1984). Hypohaptoglobinemia: a possible predisposition to epilepsy. *Trans. Assoc. Am. Physicians* 97:56-62.
- Raymond S (1962). A convenient apparatus for vertical gel electrophoresis. *Clin Chem.* 8:455-470.
- Rwiza HT, Kilonzo GP, Haule J (1992). Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian District: A community-based study. *Epilepsia* 33:1051-1056.
- Saccucci P, Verdecchia M, Piciullo A, Bottini N, Rizzo R, Gloria-Bottini F, Lucarelli P, Curatolo P (2004). Convulsive disorder and genetic polymorphism. Association of idiopathic generalized epilepsy with haptoglobin polymorphism. *Neurogenetics* 5:245-248.
- Sadrzadeh SM, Saffari Y, Bozorgmehr J (2004). Haptoglobin phenotypes in epilepsy. *Clin. Chem.* 50:1095-1097.
- Schwanger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walter-Sack I (1999). Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. *Epilepsia* 40:345-350.
- Stocker R, Keaney JF Jr. (2004). Role of oxidative modifications in atherosclerosis. *Physiol. Rev.* 84:1381-1478.
- Tan TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang Wn, Chuang YC (2009). Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. *Epilepsia* 50(6):1579-1586.
- Tekle-Haimanot R, Forsgren L, Ekstedt J. (1997). Incidence of epilepsy in rural central Ethiopia. *Epilepsia* 38:541-546.
- Temple ME, Luzier AB, Kazierad DJ (2000). Homocysteine as a risk factor for atherosclerosis. *Ann. Pharmacother.* 34:57-65.
- Tseng CF, Lin CC, Huang HY, Liu HC, Mao SJ (2004). Antioxidant role of human haptoglobin. *Proteomics* 4:2221-2228.
- Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC (2006). Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. *J. Cell. Biochem.* 98:1150-1162.
- Yagi K (1976). A simple fluorometric assay for lipoperoxide in blood plasma. *Biochem. Med.* 15:212-216.

African Journal of Biochemistry Research

Related Journals Published by Academic Journals

- *International Journal of Plant Physiology and Biochemistry*
- *African Journal of Biotechnology*
- *Journal of Developmental Biology and Tissue Engineering*



academicJournals